Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avidas Pharmaceuticals has acquired North American rights to several prescription and over-the-counter dermatology products from Crown Laboratories.
Subscribe to our email newsletter
The agreement between Avidas and Crown includes development collaboration and additional dermatology products. Financial terms of the transaction were not disclosed.
The first products to be launched by Avidas from this acquisition will be Scalacort, a prescription corticosteroid for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, and Scalacort DK, a comprehensive system for the management of dermatitis of the scalp and other affected areas. Scalacort and Scalacort DK will be sold through the Avidas sales force to dermatologists throughout the US.
According to Avidas, this agreement expands the company’s dermatology franchise and adds products that address chronic dermatologic conditions including scalp psoriasis and seborrheic dermatitis.
Margie Gardner, CEO of Avidas, said: “These product acquisitions, together with other as yet undisclosed acquisitions, add significant value to Avidas and allow us to further leverage our solid US commercial infrastructure in the dermatology market. We look forward to collaborating with Crown to bring important additional new therapies to patients to improve their conditions and ultimately, their quality of life.”